New EASL Guidelines For HBV Infection Released

The new European Association for the Study of the Liver (EASL) clinical practice guidelines for hepatitis B virus infection identifies new management strategies for an ...

First HCV DAAs Approved for Children and Adolescents

Harvoni (ledipasvir and sofosbuvir) has been approved for children with HCV genotype 1, 4, 5, or 6 infection. Sovaldi (sofosbuvir) has been approved for children ...

Investigational DAA Combo Improves Patient-Reported Outcomes

An investigational direct-acting antiviral treatment combination improves patient-reported outcomes in addition to sustained virologic response in patients with HCV, especially patients with cirrhosis.

Treatment Failure Linked With Newer HCV Antivirals

While direct-acting antivirals represent an important advance in the treatment of hepatitis C virus infection, further investigation is needed to understand the reasons for the ...

Shorter Ledipasvir/Sofosbuvir Treatment Highly Effective in HCV GT1

The 8-week regimen of LDV/SOF for HCV genotype 1 induced sustained virologic response at 12 weeks in nearly all patients treated.

Latest News

Tenofovir During Pregnancy Prevents Prenatal Transmission of HBV

Tenofovir During Pregnancy Prevents Prenatal Transmission of HBV

Women with a high hepatitis B viral load who receive tenofovir during pregnancy have a significantly reduced risk for passing on the virus to their child, without an increase in the risk of adverse events.

Sharp Increase in Maternal HCV Infection in US

Sharp Increase in Maternal HCV Infection in US

Hepatitis C virus infections among pregnant women have nearly doubled between 2009 and 2014 in the United States according to the CDC.

HCV Infection Doubled in Reproductive-aged Women From 2006 to 2014

HCV Infection Doubled in Reproductive-aged Women From 2006 to 2014

Researchers found that there was a doubling in the number of reproductive-aged women with acute and past or present HCV infection in the National Notifiable Disease Surveillance System.

CDC: Rise in HCV Infections Tripled in Last 5 Years

CDC: Rise in HCV Infections Tripled in Last 5 Years

The CDC reports that new hepatitis C virus infections in the US have nearly tripled over 5 years.

Phase 3 Study Finds Pan-Genotypic HCV Regimen Highly Efficacious

Phase 3 Study Finds Pan-Genotypic HCV Regimen Highly Efficacious

Findings from the EXPEDITION-1 study, a phase 3 trial, evaluated the efficacy and safety of glecaprevir/pibrentasvir for the treatment of chronic HCV infection in patients with genotype 1, 2, 4, 5, or 6 and compensated cirrhosis.

Investigational Ledipasvir/Sofosbuvir Dose Safe in Children With HCV

Investigational Ledipasvir/Sofosbuvir Dose Safe in Children With HCV

Investigational dosage of once-daily ledipasvir/sofosbuvir was safe and highly efficacious in children age 6 to 11 with chronic HCV infection.

Clinical Practice Update on Managing Patients Cured of HCV Infection

Clinical Practice Update on Managing Patients Cured of HCV Infection

Patients with chronic HCV infection who have achieved a sustained virologic response with treatment are considered cured, but they may still be at risk for complications such as hepatocellular carcinoma. The American Gastroenterological Association Institute addresses these issues in its clinical practice update on managing patients cured of HCV infection.

Statins Reduce Risk of Cirrhosis Decompensation in HBV, HCV

Statins Reduce Risk of Cirrhosis Decompensation in HBV, HCV

Statin use decreased rates of decompensation in patients with liver cirrhosis due to HBV and HCV infections and, to a lesser extent, in patients with alcohol-induced cirrhosis. Mortality rates were also reduced in statin users with HBV-related cirrhosis.

Hepatitis B and C Infection May Increase Risk for Parkinson Disease

Hepatitis B and C Infection May Increase Risk for Parkinson Disease

While prior studies have found an association between hepatitis C and the risk for Parkinson disease, the association between hepatitis B and Parkinson disease is new and needs further confirmation.

Pharmacist Interventions Can Help to Optimize HCV Treatment

Pharmacist Interventions Can Help to Optimize HCV Treatment

Clinical pharmacists can encourage preventive measures on reducing HCV transmission, increase education adherence, assist in initiating HCV treatment, assist in monitoring clinical and adverse effects, and facilitate medication acquisition.

Sign Up for Free e-newsletters